FDA pan­el votes yes on In­di­v­ior’s opi­oid ad­dic­tion drug

In­di­v­ior’s (LON: IN­DV) ex­per­i­men­tal drug to fight opi­oid ad­dic­tion may soon get the green light from reg­u­la­tors fol­low­ing a near-unan­i­mous vote for ap­proval by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.